<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589732</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0077</org_study_id>
    <nct_id>NCT00589732</nct_id>
  </id_info>
  <brief_title>Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent</brief_title>
  <acronym>VAL-SUPPRES</acronym>
  <official_title>Valsartan for SUPpression of Plaque Volume and Restenosis After Drug-Eluting Stent (The VAL-SUPPRESS TRial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate that angiotensin-converting enzyme (ACE) inhibitors and angiotensin-converting&#xD;
      enzyme receptor blockers (ARBs) reduce the risk of restenosis after DES implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stimulation of the angiotensin II type 1 (AT1) receptors after arterial injury promotes&#xD;
      vascular smooth muscle cell (VSMC) migration, proliferation, and extracellular matrix&#xD;
      production, leading to the hope that blockade of this receptor by angiotensin-converting&#xD;
      enzyme inhibitors (ACEI) or specific (AT1) receptor antagonists (ARBs) might reduce intimal&#xD;
      hyperplasia. However, despite confirmatory evidence in several animal models of restenosis,&#xD;
      the large scale MERCATOR and MARCATOR trials of cilazapril with balloon angioplasty failed to&#xD;
      show benefit. In 1999, Kondo reported the results of a randomized pilot trial of 100 patients&#xD;
      who received Palmaz-Schatz stents and were randomized to receive the ACE inhibitor quinapril&#xD;
      or placebo. The volume of neointimal hyperplasia assessed by IVUS was significantly less&#xD;
      quinapril than the control group (18 ± 0.6 mm3 vs. 25 ± 0.6 mm3; p &lt; 0.05). The quinapril&#xD;
      group's restenosis rate was 16%, with the quinapril benefit being observed only in patients&#xD;
      with the D/D and I/D genotypes. Also, other study reported on a consecutively treated cohort&#xD;
      of 1,598 stented patients, noting that ACE inhibitor usage at the time and after stenting&#xD;
      reduced the risk of subsequent revascularization dramatically (adjusted odds ratio, 0.46; p =&#xD;
      0.001). In the ValPREST trial which is a single-center randomized trial of patients receiving&#xD;
      stents for type B2/C lesions, comparing valsartan (and ARV) 80 mgs daily with open treatment,&#xD;
      patients randomized to valsartan had a 19% incidence of restenosis compared with 39% in the&#xD;
      open treatment arm (p = 0.005).&#xD;
&#xD;
      Recently, several randomized studies were conducted to compare the safety and efficacy of the&#xD;
      two leading drug-eluting stent (DES). However, data on the association of ARBs for&#xD;
      suppression of neointimal hyperplasia are limited in the DES era. Therefore, a pivotal&#xD;
      randomized study is warranted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic in-stent late-loss (target vessel)</measure>
    <time_frame>at 8-month follow-up.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Major cardiac adverse events including death, Q-MI, Non Q-MI, and target lesion or vessel revascularization -Delta change in percent atheroma area and volume</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Major cardiac adverse events including death, Q-MI, Non Q-MI, and target lesion or vessel revascularization</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each component of MACE</measure>
    <time_frame>3 days in average</time_frame>
    <description>3 day hospitalization is normal for index procedure and outcome needs to be measured at discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each component of MACE</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each component of MACE</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment restenosis rate</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment late loss</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent atheroma volume of 10mm length by IVUS examination (non-target vessel) in IVUS-substudy</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Valsartan treatment gorup</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan 160mg per day group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Valsartan treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No valsartan treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan 160mg per day</description>
    <arm_group_label>Valsartan treatment gorup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical 1) Patients with angina and documented ischemia or patients with documented&#xD;
             silent ischemia 2) Patients who are eligible for intracoronary stenting 3) Age &gt;18&#xD;
             years, &lt;75 ages 4) Preserved left ventricular ejection fraction (&gt;40%) 5) Written&#xD;
             informed consent to the study protocol 6) Patients with hemodynamic stability and&#xD;
             appropriate blood pressure, which were suitable for administration of valsartan 160mg&#xD;
&#xD;
          2. Angiographic: Patients who have&#xD;
&#xD;
        1) Significant ischemic narrowing (target vessel)&#xD;
&#xD;
          1. De novo coronary lesion (no restriction of lesion length)&#xD;
&#xD;
          2. Percent diameter stenosis ≥50% by visual estimate&#xD;
&#xD;
          3. Reference vessel size ≥2.5 mm by visual estimation&#xD;
&#xD;
          4. Lesions suitable for stenting&#xD;
&#xD;
        And/Or&#xD;
&#xD;
        2) Non-significant non-ischemic intermediate narrowing (non-target vessel)&#xD;
&#xD;
          1. Percent diameter stenosis 20%~50% by visual estimate&#xD;
&#xD;
          2. No objective evidence of ischemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients received a Angiotensin converting enzyme inhibitor (ACE-I) or ACE-receptor&#xD;
             blockers (ARBs) in the previous week prior to enrollment&#xD;
&#xD;
          2. History of bleeding diathesis or coagulopathy&#xD;
&#xD;
          3. Pregnant&#xD;
&#xD;
          4. Known hypersensitivity or contra-indication to contrast agent and heparin&#xD;
&#xD;
          5. Limited life-expectancy (less than 1 year)&#xD;
&#xD;
          6. Acute ST-elevation myocardial within 1 week&#xD;
&#xD;
          7. Characteristics of lesion 1) Left main disease 2) In-stent restenosis 3) Graft vessels&#xD;
&#xD;
          8. Hematological disease (Neutropenia &lt;3000/mm3, Thrombocytopenia &lt;100,000/mm3)&#xD;
&#xD;
          9. Hepatic dysfunction, liver enzyme (ALT and AST) elevation &gt;3 times normal&#xD;
&#xD;
         10. Renal dysfunction, creatinine &gt;2.0mg/dL&#xD;
&#xD;
         11. Contraindication to aspirin and clopidogrel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Catholic Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>December 31, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>August 7, 2012</last_update_submitted>
  <last_update_submitted_qc>August 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>M.D., Ph.D.,Professor of Medicine Asan Medical Center, University of Ulsan, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>stents</keyword>
  <keyword>angiotensin-converting enzyme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

